Mast cells, TGF-β1 and myofibroblasts expression in lupus nephritis outcome

Lupus

Volumn 14, Issue 10, 2005, Pages 814-821

  Ravinal, R Cuan ^a   Costa, R S ^a   Coimbra, T M ^a   Dantas, M ^a   Dos Reis, M A ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

SM actin; Lupus nephritis; Mast cells; Renal fibrosis; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA1; TRYPTASE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; HUMAN TISSUE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MAST CELL; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ACTINS; ADULT; BIOLOGICAL MARKERS; FEMALE; FIBROBLASTS; HUMANS; KIDNEY; LUPUS NEPHRITIS; MALE; MAST CELLS; MYOCYTES, SMOOTH MUSCLE; SERINE ENDOPEPTIDASES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRYPTASES;

EID: 27744504123     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2188oa     Document Type: Article

References (41)

1. D'Agati VD. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren's syndrome and rheumatoid arthritis. In Jennette JC, Olson JL, Schwartz MM, Silva FG eds. Heptinstall's pathology of the kidney, 5th edn, vol. I. Philadelphia: Lippincott-Raven, 1998: 541-599.
2. Rahman MAA, Isenberg DA. Autoantibodies in lupus nephritis. In Lewis EJ, Schwartz MM, Korbet SM eds. Lupus nephritis. New York: Oxford University Press, 1999: 1-21.
3. Razzaque MS, Taguchi T. Factors that influence and contribute to the regulation of fibrosis. Contrib Nephrol 2003; 139: 1-11.
4. Wilson HM, Walbaum D, Rees AJ. Macrophages and the kidney. Curr Opin Nephrol Hypertens 2004; 13: 285-290.
5. Kluth DC, Erwig LP, Rees AJ. Multiple facets of macrophages in renal injury. Kidney Int 2004; 66: 542-557.
6. Ehara T, Shigematsu H. Mast cells in the kidney. Nephrology (Carlton) 2003; 8: 130-138.
7. Eddy AA. Mast cells find their way to the kidney. Kidney Int 2001; 60: 375-377.
8. Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 2000; 53: 858-862.
9. Hiromura K, Kurosawa M, Yano S, Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis 1998; 32: 593-599.
10. Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol 2001; 12: 1668-1676.
11. Gruber BL. Mast cells in the pathogenesis of fibrosis. Curr Rheumatol Rep 2003; 5: 147-153.
12. Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE. Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int 2003; 64: 906-913.
13. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
14. Tamaki K, Okuda S. Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 2003; 139: 44-65.
15. Gruber BL, Marchese MJ, Kew RR. Transforming growth factor-beta 1 mediates mast cell chemotaxis. J Immunol 1994; 152: 5860-5867.
16. Moriyama T, Imai E. Role of myofibroblasts in progressive renal diseases. Contrib Nephrol 2003; 139: 120-140.
17. Zhang G, Moorhead PJ, el Nahas M. Myofibrobalst and the progression of experimental glomerulonephritis. Exp Nephrol 1995; 3: 308-318.
18. Ravinal RC, Costa RS, Coimbra TM et al. Classes, activity and chronicity indices, and alpha-smooth muscle actin expression as prognostic parameters in lupus nephritis outcome. Lupus 2002; 11: 82-87.
19. Alpers CE, Hudkins KL, Gown AM, Johnson RJ. Enhanced expression of "muscle-specific" actin in glomerulonephritis. Kidney Int 1992; 41: 1134-1142.
20. Johnson RJ, Floege J, Yoshimura A, Lida H, Couser WG, Alpers CE. The activated mesangial cell: a glomerular "myofibroblast"? J Am Soc Nephrol 1992; 2: 190-197.
21. Najafi CC, Korbert SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163.
22. Kobert SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohdes RD. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914.
23. Appel GB, Silva F, Pirani CL, Meltzer JI, Estes D. Renal involvement in systemic lupus erythematosus: a survey of 56 patients emphasizing histologic classification. Medicine 1978; 57: 371-410.
24. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885.
25. Mitjavila F, Pac V, Moga I, Vidaller A, Carrera M, Pujol R. Clinico-pathological correlation and prognostic factors in lupus nephritis. Clin Exp Rheumatol 1997; 15: 625-631.
26. Johnson J, Nived O, Sturfelt G. Outcome in systemic lupus nephritis: a prospective study of patients from defined population. Medicine 1989; 68: 141-150.
27. Esdaile JM, Levington C, Federgreen W, Hayslet JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 1989; 72: 779-833.
28. Magil AB, Puterman ML, Ballon HS et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 1988; 34: 511-517.
29. McLaughlin J, Gladman DD, Urowitz MB, Bombardier C, Farewell VT, Cole E. Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 1991; 34: 1268-1273.
30. Ehara T, Shigematsu H. Contribution of mast cells to the tubulointerstitial lesion in IgA nephritis. Kidney Int 1998; 54: 1675-1683.
31. Kurusu A, Suzuki Y, Horikoshi S, Shirato I, Tomino Y. Relationship between mast cells in the tubulointerstitium and prognosis of patients with IgA nephropathy. Nephron 2001; 89: 391-397.
32. Danilewicz M, Wagrowska-Danilewicz M. Quantitative analysis of interstitial mast cells in lupus and non-lupus membranous glomerulopathy. Pol J Pathol 2001; 52: 211-217.
33. Danilewicz M, Wagrowska-Danilewicz M. Quantitative analysis of the interstitial mast cells in idiopathic mesangiocapillary glomerulonephritis type I. Nefrologia 2001; 21: 253-259.
34. Danilewicz M, Wagrowska-Danilewicz M. Quantitative analysis of interstitial mast cells in AA and AL renal amyloidosis. Pathol Res Pract 2002; 198: 413-419.
35. Danilewicz M, Wagrowska-Danilewicz M. Immunohistochemical analysis of the interstitial mast cells in acute rejection of human renal allografts. Med Sci Monit 2004; 10: BR151-156.
36. Goto E, Honjo S, Yamashita H, Shomori K, Adachi H, Ito H. Mast cells in human allografted kidney: correlation with interstitial fibrosis. Clin Transplant 2002; 16(Suppl 8): 7-11.
37. Otsubo S, Nitta K, Uchida K, Yumura W, Nihei H. Mast cells and tubulointerstitial fibrosis in patients with ANCA-associated glomerulonephritis. Clin Exp Nephrol 2003; 7: 41-47.
38. Toth T, Toth-Jakatics R, Jimi S, Ihara M, Urata H, Takebayashi S. Mast cells in rapidly progressive glomerulonephritis. J Am Soc Nephrol 1999; 10; 1498-1505.
39. Toth T, Toth-Jakatics R, Jimi S, Takebayashi S. Increased density of interstitial mast cells in amyloid A renal amyloidosis. Mod Pathol 2000; 13: 1020-1028.
40. Pardo J, Diaz L, Errasti P et al. Mast cells in chronic rejection of human renal allografts. Virchows Arch 2000; 437: 167-172.
41. Solari V, Unemoto K, Piaseczna Piotrowska A, Puri P. Increased expression of mast cells in reflux nephropathy. Pediatr Nephrol 2004; 19: 157-163.